Compositions and methods for inhibiting expression of RRM2 genes

Patent metadata

Field	Value
Publication number	US-9938531-B2
Application number	US-201715415415-A
Country	US
Kind code	B2
Filing date	Jan 25, 2017
Priority date	Oct 18, 2010
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

First claim

We claim:

1. A double-stranded ribonucleic acid molecule for inhibiting the expression of ribonucleotide reductase M2 (RRM2) gene, comprising a first strand and a second strand, wherein the first strand comprises the nucleotide sequence of SEQ ID NO: 242, 289, or 315.

2. The double-stranded ribonucleic acid molecule of claim 1 , wherein the first strand is less than about 30 nucleotides in length.

3. The double-stranded ribonucleic acid molecule of claim 2 , wherein the double-stranded ribonucleic acid molecule comprises at least one modified nucleotide.

4. The double-stranded ribonucleic acid molecule of claim 3 , wherein the modified nucleotide is selected from the group consisting of: 2′-O-methyl modified nucleotide, nucleotide comprising a 5′-phosphorothioate group, 2′-deoxy-2′-fluoro modified nucleotide, 2′-deoxy-modified nucleotide, locked nucleotide, abasic nucleotide, inverted deoxythymidine, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, phosphoramidate, and non-natural base comprising nucleotide.

5. The double-stranded ribonucleic acid molecule of claim 2 , wherein the first strand is at least partially complementary to the second strand.

6. The double-stranded ribonucleic acid molecule of claim 5 , wherein the second strand comprises the nucleotide sequence of SEQ ID NO: 9, 56, or 82.

7. The double-stranded ribonucleic acid molecule of claim 6 , wherein the first strand and the second strand each comprise at least one modified nucleotide.

8. The double-stranded ribonucleic acid molecule of claim 7 , wherein the modified nucleotide in the first strand and the modified nucleotide in the second strand is selected from the group consisting of: 2′-O-methyl modified nucleotide, nucleotide comprising a 5′-phosphorothioate group, 2′-deoxy-2′-fluoro modified nucleotide, 2′-deoxy-modified nucleotide, locked nucleotide, abasic nucleotide, inverted deoxythymidine, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, phosphoramidate, and non-natural base comprising nucleotide.

9. The double-stranded ribonucleic acid molecule of claim 6 , wherein said double-stranded ribonucleic acid molecule comprises a sequence pair selected from the group consisting of SEQ ID NOs.: 9/242, 56/289, or 82/315.

10. The double-stranded ribonucleic acid molecule of claim 7 , wherein the first strand or the second strand further comprises a 3′ overhang of 1-5 nucleotides in length.

11. The double-stranded ribonucleic acid molecule of claim 10 , wherein the 3′ overhang comprises nucleotides linked by one or more phosphorothioate groups.

12. The double-stranded ribonucleic acid molecule of claim 11 , wherein said 3′ overhang comprises uracil.

13. The double-stranded ribonucleic acid molecule of claim 3 , wherein said double-stranded ribonucleic acid molecule comprises more than one modified nucleotide.

14. The double-stranded ribonucleic acid molecule of claim 13 , wherein said double-stranded ribonucleic acid molecule comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-deoxy-2′-fluoro modified nucleotide, or at least one nucleotide comprising a 5′-phosphorothioate group.

15. The double-stranded ribonucleic acid molecule of claim 8 , wherein said double-stranded ribonucleotic acid molecule is conjugated to a ligand.

16. The double-stranded ribonucleic acid molecule of claim 14 , wherein said double-stranded ribonucleotic acid molecule is conjugated to a ligand.

17. A cell, tissue or non-human organism comprising a double-stranded ribonucleic acid molecule comprising a first strand and a second strand, wherein said first strand comprises the nucleotide sequence of SEQ ID NO: 242, 289, or 315.

18. A pharmaceutical composition comprising: (i) a double-stranded ribonucleic acid molecule wherein said double-stranded ribonucleic acid molecule comprises a first strand and a second strand, wherein the first strand comprises the nucleotide sequence of SEQ ID NO: 242, 289, or 315, and (ii) a pharmaceutically acceptable carrier.

Assignees

• Arrowhead Pharmaceuticals Inc

Inventors

• Boylan John Frederick
• Bramlage Birgit
• Hossbach Markus
• Reidhaar-Olson John

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C12N2310/33

  of the base · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title

• C12Y117/04001

  Ribonucleoside-diphosphate reductase (1.17.4.1) · CPC title

• C12N2310/346

  having a combination of backbone and sugar modifications · CPC title